Literature DB >> 29611059

New Developments in the Genetics of Inclusion Body Myositis.

Kyla A Britson1,2, Stephanie Y Yang1,3, Thomas E Lloyd4.   

Abstract

PURPOSE OF REVIEW: Our goal is to review the recent literature pertaining to the genetics of sporadic inclusion body myositis (IBM). RECENT
FINDINGS: In a study of 252 IBM patients, the class II MHC allele HLA-DRB1*03:01 showed the most significant association with IBM, and that risk could be largely attributed to amino acids within the peptide-binding pocket. Candidate gene sequencing identified rare missense variants in proteins regulating protein homeostasis including VCP and SQSTM1. An unbiased approach employing exome sequencing of genes encoding rimmed vacuole proteins identified FYCO1 variants in IBM. Ongoing GWAS approaches may shed new light on genetic risk factors for IBM. Many variants have been reported at an increased frequency in IBM in small studies; however, only HLA association has shown genome-wide significance. Future studies are needed to validate variants in larger cohorts and to understand the molecular roles these risk factors play in IBM.

Entities:  

Keywords:  FYCO1; Follistatin; HLA; Inclusion body myositis; SQSTM1; VCP

Mesh:

Substances:

Year:  2018        PMID: 29611059      PMCID: PMC6374100          DOI: 10.1007/s11926-018-0738-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  76 in total

1.  VCP mutations in familial and sporadic amyotrophic lateral sclerosis.

Authors:  Max Koppers; Marka M van Blitterswijk; Lotte Vlam; Paulina A Rowicka; Paul W J van Vught; Ewout J N Groen; Wim G M Spliet; JooYeon Engelen-Lee; Helenius J Schelhaas; Marianne de Visser; Anneke J van der Kooi; W-Ludo van der Pol; R Jeroen Pasterkamp; Jan H Veldink; Leonard H van den Berg
Journal:  Neurobiol Aging       Date:  2011-11-10       Impact factor: 4.673

2.  Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis.

Authors:  Anne-Katrin Güttsches; Stefen Brady; Kathryn Krause; Alexandra Maerkens; Julian Uszkoreit; Martin Eisenacher; Anja Schreiner; Sara Galozzi; Janine Mertens-Rill; Martin Tegenthoff; Janice L Holton; Matthew B Harms; Thomas E Lloyd; Matthias Vorgerd; Conrad C Weihl; Katrin Marcus; Rudolf A Kley
Journal:  Ann Neurol       Date:  2017-01-27       Impact factor: 10.422

Review 3.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

4.  Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine.

Authors:  Jakob Hansen; Claus Brandt; Anders R Nielsen; Pernille Hojman; Martin Whitham; Mark A Febbraio; Bente K Pedersen; Peter Plomgaard
Journal:  Endocrinology       Date:  2010-11-10       Impact factor: 4.736

5.  A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.

Authors:  Jerry R Mendell; Zarife Sahenk; Vinod Malik; Ana M Gomez; Kevin M Flanigan; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Eric Meadows; Sarah Lewis; Lyndsey Braun; Kim Shontz; Maria Rouhana; Kelly Reed Clark; Xiomara Q Rosales; Samiah Al-Zaidy; Alessandra Govoni; Louise R Rodino-Klapac; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-17       Impact factor: 11.454

6.  Phenotypic variability in three families with valosin-containing protein mutation.

Authors:  S Spina; A D Van Laar; J R Murrell; R L Hamilton; J K Kofler; F Epperson; M R Farlow; O L Lopez; J Quinlan; S T DeKosky; B Ghetti
Journal:  Eur J Neurol       Date:  2012-08-20       Impact factor: 6.089

7.  A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.

Authors:  L A Love; R L Leff; D D Fraser; I N Targoff; M Dalakas; P H Plotz; F W Miller
Journal:  Medicine (Baltimore)       Date:  1991-11       Impact factor: 1.889

8.  Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms.

Authors:  F L Mastaglia; A Rojana-udomsart; I James; M Needham; T J Day; L Kiers; J A Corbett; A M Saunders; M W Lutz; A D Roses
Journal:  Neuromuscul Disord       Date:  2013-09-19       Impact factor: 4.296

9.  The role of myostatin in muscle wasting: an overview.

Authors:  Yulia Elkina; Stephan von Haehling; Stefan D Anker; Jochen Springer
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-07-26       Impact factor: 12.910

10.  Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups.

Authors:  Simon Rothwell; Robert G Cooper; Ingrid E Lundberg; Frederick W Miller; Peter K Gregersen; John Bowes; Jiri Vencovsky; Katalin Danko; Vidya Limaye; Albert Selva-O'Callaghan; Michael G Hanna; Pedro M Machado; Lauren M Pachman; Ann M Reed; Lisa G Rider; Joanna Cobb; Hazel Platt; Øyvind Molberg; Olivier Benveniste; Pernille Mathiesen; Timothy Radstake; Andrea Doria; Jan De Bleecker; Boel De Paepe; Britta Maurer; William E Ollier; Leonid Padyukov; Terrance P O'Hanlon; Annette Lee; Christopher I Amos; Christian Gieger; Thomas Meitinger; Juliane Winkelmann; Lucy R Wedderburn; Hector Chinoy; Janine A Lamb
Journal:  Ann Rheum Dis       Date:  2015-09-11       Impact factor: 19.103

View more
  4 in total

1.  Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis.

Authors:  Adam Amlani; May Y Choi; Mark Tarnopolsky; Lauren Brady; Ann E Clarke; Ignacio Garcia-De La Torre; Michael Mahler; Heinrike Schmeling; Claire E Barber; Michelle Jung; Marvin J Fritzler
Journal:  Front Immunol       Date:  2019-04-09       Impact factor: 7.561

Review 2.  Programmed Cell Death Pathways in the Pathogenesis of Idiopathic Inflammatory Myopathies.

Authors:  Jia Shi; Mingwei Tang; Shuang Zhou; Dong Xu; Jiuliang Zhao; Chanyuan Wu; Qian Wang; Xinping Tian; Mengtao Li; Xiaofeng Zeng
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

Review 3.  Inclusion Body Myositis and Neoplasia: A Narrative Review.

Authors:  Laura Damian; Cristian Cezar Login; Carolina Solomon; Cristina Belizna; Svetlana Encica; Laura Urian; Ciprian Jurcut; Bogdan Stancu; Romana Vulturar
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

4.  Muscle Transcriptomics Shows Overexpression of Cadherin 1 in Inclusion Body Myositis.

Authors:  Chiseko Ikenaga; Hidetoshi Date; Motoi Kanagawa; Jun Mitsui; Hiroyuki Ishiura; Jun Yoshimura; Iago Pinal-Fernandez; Andrew L Mammen; Thomas E Lloyd; Shoji Tsuji; Jun Shimizu; Tatsushi Toda; Jun Goto
Journal:  Ann Neurol       Date:  2022-02-11       Impact factor: 11.274

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.